Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians
04 Julho 2023 - 9:30AM
Business Wire
- Dexcom G7 is the most accurate CGM system1
approved by Health Canada, building on the trusted performance of
Dexcom CGM, which is clinically proven to lower A1C, reduce
hypoglycemia, and improve time in range2,3,4.
- Made with users in mind, Dexcom G7 combines simplicity and
power, introducing a better way to manage diabetes2,3,4.
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time
continuous glucose monitoring (rtCGM) for people with diabetes,
announced today that Health Canada has approved the next-generation
Dexcom G7 Continuous Glucose Monitoring System for people with all
types of diabetes, ages two years and older.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230704730937/en/
Dexcom G7 receives Health Canada
approval. Compatible smart devices sold separately:
dexcom.com/compatibility. (Photo: Business Wire)
Diabetes is a complex and burdensome condition affecting more
than 3 million Canadians6. It requires around-the-clock management
of glucose levels and daily treatment decisions to manage the
disease. Health Canada approval of Dexcom G7 gives Canadians access
to a game changing technology that makes managing diabetes easier,
and has been shown to reduce hospitalizations and emergency room
visits due to hypoglycemia by up to 42 per cent *,7.
“For more than two decades, Dexcom has had a singular focus on
sensor technology, consistently working to evolve our CGM systems
by listening to the needs of people with diabetes and their
caregivers, making diabetes management easier for people around the
world,” said André Côté, Vice President and General Manager, Dexcom
Canada. “With our latest advancements in sensor technology and
software integrations, we’re entering a new era of diabetes care
with continuous glucose monitoring at the centre. Dexcom G7 builds
on the innovation that our previous CGM systems have brought to the
lives of Canadians. With greater accuracy, a simplified user
experience, proven results and extensive digital connectivity, our
next-generation Dexcom G7 will support greater quality of life and
improved outcomes for people with diabetes, and we couldn’t be more
excited to bring it to Canada by the end of 2023.”
Dexcom G7 introduces a powerful yet simple way to help users
gain greater control of their diabetes, so that they can manage the
disease more confidently. Its low-profile, all-in-one sensor and
transmitter warms up two times faster than any other CGM on the
market †,5 , and empowers users to see real-time glucose readings
sent automatically to their compatible smart device‡ or receiver,
without the need to scan or prick their finger routinely.§
Featuring a suite of customizable alerts, Dexcom G7 can warn of
high or low glucose levels with a predictive urgent low alert to
help avoid potentially dangerous hypoglycemic events, and can help
users spend more time in range.**,2,3,4 Users can also share
information with family, loved ones and care teams anywhere,
anytime through industry-leading remote monitoring and reporting
capabilities††.
“Real-time continuous glucose monitoring (rtCGM) has become the
standard of care for many people living with diabetes, with
clinical evidence supporting its effectiveness for reducing A1C,
increasing time spent in the target glucose range, reducing the
number of low glucose events and reducing the time spent with
dangerous low glucose2,3,4,” said Alice Cheng, Endocrinologist at
Trillium Health Partners, Credit Valley Hospital and St. Michael’s
Hospital (Unity Health Toronto). “With approval of Dexcom G7, the
newest glucose sensor to come to Canada, patients will have a new,
simple to start and easy to use tool in their diabetes management
toolbox to effectively manage their diabetes and make important
health decisions backed by health data and proven results.”
Zooming into the new features and enhancements with Dexcom
G7
- The smallest Dexcom sensor ever – 60 per cent smaller than
Dexcom G6 – with multiple approved wear locations, for more
comfortable and discreet wear‡‡
- An all-in-one sensor and transmitter, simplifying the entire
CGM system and experience
- 30-minute sensor warm up, two times faster warmup than any
other CGM for a quick, simple start 5,8
- A 12-hour grace period to replace finished sensors for a more
seamless transition between sessions, offering more convenience and
flexibility to users
- Improved alert customization5 to meet individual user needs and
preferences
- Redesigned and simplified mobile app with Dexcom Clarity
integration§§,***
As the most connected CGM brand in the world†††,1, Dexcom is
actively working with its insulin pump partners to integrate Dexcom
G7 into current and future automated insulin delivery systems.
While approved by Health Canada, Dexcom G7 is not yet available
for purchase. Dexcom Canada is working diligently to bring Dexcom
G7 to Canadians living with diabetes by the end of 2023. To learn
what’s new with Dexcom G7 and how to sign up to be the first to
know when product becomes available, go to
https://www.dexcom.com/G7Canada.
About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California in the United States, and
with operations in Canada, Dexcom has emerged as a leader in
diabetes care technology. By listening to the needs of users,
caregivers, and providers, Dexcom simplifies and improves diabetes
management around the world. For more information about Dexcom CGM,
visit www.dexcom.com.
_______________________________________
* Study evaluated insulin-treated patients (n = 41,753) from the
Kaiser Permanente Northern California (KPNC) Diabetes Registry with
no prior history of CGM use. † Dexcom G7 can complete warmup within
30 minutes, whereas other CGM brands require up to an hour or
longer. ‡ For a list of compatible devices, please visit
dexcom.com/compatibility. § If your glucose alerts and readings
from the Dexcom G7 do not match symptoms or expectations, use a
blood glucose meter to make diabetes treatment decisions. **
Results obtained with a prior generation Dexcom CGM System. ††
Separate Follow app and internet connection required. Users should
always confirm readings on the Dexcom G7 app or receiver before
making treatment decisions. ‡‡ Compared to a prior generation
Dexcom CGM System. §§ Healthcare providers can register for Dexcom
Clarity at clarity.dexcom.com/professional/registration. *** An
internet connection is required for users to send their glucose
data to Dexcom Clarity via a compatible smart device:
dexcom.com/compatibility. Healthcare providers will only be able to
view a patient’s glucose data if the patient elects to share it
with them through Dexcom Clarity. ††† Not all connections are
available in Canada. To learn more about insulin pump integrations
and compatibility with Dexcom CGM Systems, visit
dexcom.com/integrate.
1 Dexcom, Data on file, 2023 2 Beck RW, et al. JAMA.
2017;317(4):371-378. 3 Welsh JB, et al. J Diabetes Sci Technol.
2022:19322968221099879. 4 Beck RW, et al. Ann Intern Med.
2017;167(6):365-374. 5 Dexcom G7 User Guide 6 Public Health Agency
of Canada. Framework for diabetes in Canada. Government of Canada
Website. Published October 5, 2022. Accessed June 23, 2023.
https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html
7 Karter AJ, et al. JAMA. 2021;325(22):2273-2284 8 Freestyle Libre
2 User Manual
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230704730937/en/
Media Contact: Alena Atkinson Veritas Communications
atkinson@veritasinc.com
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024